UPDATE : Tuesday, October 15, 2019
상단여백
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
HLB merges with Elevar to own rivoceranib rights by Jeong Sae-im 2019-10-14 14:43
Samsung Bioepis to present data of Etanercept biosimilar in Europe by Lee Han-soo 2019-10-10 11:31
‘Kosdaq firms listed for exceptional tech need special monitoring’ by Jeong Sae-im 2019-10-07 15:51
SK Plasma launches human immunoglobulin in Brazil by Lee Han-soo 2019-10-07 11:23
라인
‘New law to support advanced biopharmaceuticals, ensure safety’ by Lee Hye-seon 2019-10-04 15:18
Samsung execs pass buck to biotech subsidiaries for destroying evidence by Jeong Sae-im 2019-10-04 11:42
Samsung Bioepis releases P3 results of Bevacizumab biosimilar in EU by Lee Han-soo 2019-09-27 11:37
‘Samsung BioLogics destroyed evidence to hide accounting fraud for months’ by Jeong Sae-im 2019-09-26 15:24
Celltrion to start marketing Herzuma in Middle East by Lee Han-soo 2019-09-26 15:02
라인
Helixmith blames hospital for absurd drug mix-up by Jeong Sae-im 2019-09-25 13:42
Court rejects Kolon’s appeal over Invossa license revocation by Jeong Sae-im 2019-09-25 11:18
FDA recommends Kolon to remanufacture Invossa’s second fluid by Jeong Sae-im 2019-09-23 15:32
Dong-A ST's Aranesp biosimilar gets nod in Japan by Lee Han-soo 2019-09-23 15:31
Biotech startups seek IPO via ‘growth potential exception’ policy by Jeong Sae-im 2019-09-17 11:26
라인
Top court rejects financial regulator’s retry to discipline Samsung BioLogics by Jeong Sae-im 2019-09-10 14:36
Canada OKs Celltrion's biosimilar by Lee Han-soo 2019-09-10 12:48
Samsung Bioepis launches Enbrel biosimilar in Brazil by Lee Han-soo 2019-09-10 12:21
Invossa victims furious at government, Kolon for ‘doing nothing’ by Jeong Sae-im 2019-09-09 15:47
Nobel laureate Honjo anticipates best combo in immunotherapies by Jeong Sae-im 2019-09-06 16:29
여백
여백
여백
Back to Top